Find News

Filter articles

Applied Filters

Showing 771 to 780 of 910 results

Par pharmaceutical in $100m settlement


Generic drug maker Par Pharmaceutical Companies has settled a long running dispute with Salix Pharmaceuticals over its heartburn drug Zegerid (omeprazole/sodium bicarbonate).

Cipla agrees Rifaximin licensing deal


Indian drug maker Cipla has signed a deal with Salix Pharmaceuticals allowing the US-based company exclusive rights relating to the Rifaximin Complexes patent family.

Gilead announces Sovaldi generic deal

India, US17-09-2014

US biotechnology company Gilead has agreed a licensing deal with seven Indian drug makers that will enable them to sell a generic version of a drug used to treat hepatitis C.

English High Court invalidates Symbicort patent

UK03-09-2014Legal developments

English High Court Justice Philip James Sales has found a patent covering AstraZeneca’s bestselling drug Symbicort invalid after a challenge by Israeli generic drug maker Teva.

Sandoz barred from making Remodulin generic until 2017

US01-09-2014Legal developments

Novartis’s generic arm Sandoz may not market a generic version of Maryland-based United Therapeutics’ Remodulin hypertension drug, the US District Court for the District of New Jersey ruled on Friday (August 29).

FDA accepts generic applications for three-times-weekly Copaxone


The FDA has accepted applications by generic drug makers Mylan and Novartis subsidiary Sandoz for a three-times-weekly version of blockbuster drug Copaxone, it was announced yesterday.

Novartis sues Zydus over Alzheimer and Parkinson’s disease drug


Novartis Pharmaceuticals has launched a lawsuit against generics company Zydus Noveltech and its subsidiaries, accusing them of infringing patents relating to a drug used to treat Alzheimer’s and Parkinson’s disease.

New Jersey court blocks Actavis’s generic Gralise

US21-08-2014Legal developments

The US District Court for the District of New Jersey has ruled that Actavis may not launch a generic version of California-based Depomed’s Gralise (gabapentin), it has been announced.

Hospira challenges FDA’s “unlawful” approval of Precedex generics

US20-08-2014Legal developments

Illinois-based drug company Hospira has sued the FDA, challenging its recent decision to approve generic versions of Precedex (dexmedetomidine hydrochloride).

Forest sues Lupin to protect $1.5bn Namenda

US19-08-2014Legal developments

Actavis-owned pharmaceutical company Forest, along with US-based Adamas Pharmaceuticals, has sued Indian generic drug maker Lupin for infringing seven patents directed to its Alzheimer’s drug Namenda XR (memantine hydrochloride), a once daily version of Namenda.

Showing 771 to 780 of 910 results